Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$775.01 USD

775.01
3,907,022

-31.05 (-3.85%)

Updated Nov 6, 2024 11:54 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Nektar (NKTR) Ends Bempeg Plus Opdivo Program on Study Failures

by Zacks Equity Research

Nektar's (NKTR) lead clinical program, bempeg plus Bristol-Myers' Opdivo, fails in registrational cancer studies. Nektar and Bristol-Myers decide to discontinue all bempeg plus Opdivo development programs.

J&J (JNJ) to Set the Tone for Pharma Sector's Q1 Earnings

by Zacks Equity Research

J&J's (JNJ) Pharma segment is expected to have performed above the market. It remains to be seen if sales improved in the Medical Devices segment in the first quarter.

Neena Mishra headshot

Healthcare ETFs Outperform Amid Rising Uncertainties

by Neena Mishra

Investors are seeking refuge in healthcare stocks as inflation and rates rise

Eli Lilly (LLY) Stock Moves -0.88%: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed at $308.96 in the latest trading session, marking a -0.88% move from the prior day.

Sheraz Mian headshot

Top Analyst Reports for Alphabet, Amazon & AbbVie

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Amazon.com, Inc. (AMZN), and AbbVie Inc. (ABBV).

Ekta Bagri headshot

Antibody Treatments for COVD-19 Face Challenges in the U.S.

by Ekta Bagri

With the emergence of the highly transmissible Omicron variant, the authorized antibody treatments of companies like Vir Biotechnology (VIR), Glaxo (GSK) and Regeneron (REGN) suffer setbacks due to a lack of efficacy against the same.

Biogen (BIIB) Down as Medicare Limits Coverage for Aduhelm

by Zacks Equity Research

Biogen (BIIB) stock declines after Medicare limits coverage for FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in CMS-approved studies.

VIR Stock Down on Another Setback for COVID-19 Antibody

by Zacks Equity Research

VIR and partner Glaxo suffer a setback as the FDA determines that sotrovimab is no longer authorized for use in the United States for COVID-19.

If You Invested $1000 in Eli Lilly 10 Years Ago, This Is How Much You'd Have Now

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed at $292.49 in the latest trading session, marking a +0.37% move from the prior day.

Roche (RHHBY) Actemra Application Receives Priority Review

by Zacks Equity Research

Roche (RHHBY) sBLA is seeking approval for the intravenous formulation of arthritis drug Actemra accepted and granted Priority Review in the United States.

Biogen (BIIB) Plans to Start Aduhelm Confirmatory Study in May

by Zacks Equity Research

Biogen (BIIB) expects to start the phase IV post-marketing confirmatory study of Aduhelm for Alzheimer's disease in May 2022. The estimated completion period of the study is four years.

Adagio's (ADGI) COVID-19 Antibody Meets Goals in Studies

by Zacks Equity Research

The stock price of Adagio (ADGI) surge after it reports positive preliminary data from the phase II/III studies, which evaluate its monoclonal antibody for the prevention and treatment of COVID-19.

ImmunoGen (IMGN) Files BLA for Lead Drug in Ovarian Cancer

by Zacks Equity Research

ImmunoGen (IMGN) seeks accelerated approval from the FDA for its lead candidate, mirvetuximab soravtansine, in previously treated platinum-resistant ovarian cancer. This pushes the stock price up.

Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PJP

Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Eli Lilly (LLY) closed at $291.66, marking a +0.91% move from the previous day.

Lilly (LLY) Gets CRL from FDA for Sintilimab in Lung Cancer

by Zacks Equity Research

Lilly (LLY) gets a complete response letter from the FDA for the biologics license application for sintilimab plus pemetrexed and platinum chemotherapy for treating first-line lung cancer.

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Eli Lilly (LLY) closed at $289.64, marking a +0.7% move from the previous day.

AbbVie's (ABBV) Rinvoq Gets FDA Nod for Ulcerative Colitis

by Zacks Equity Research

FDA approves AbbVie's (ABBV) Rinvoq for the treatment of moderate-to-severe ulcerative colitis in adults. This is the fourth indication for Rinvoq in the United States.

Incyte's (INCY) Going Gets Tough Due to Pipeline Setbacks

by Zacks Equity Research

The recent pipeline setbacks will weigh on Incyte's (INCY) growth trajectory and jeopardize its plans to diversify its revenue base.

Should iShares MSCI USA Min Vol Factor ETF (USMV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for USMV

Nektar (NKTR) Plunges on Bempeg's Melanoma Study Failure

by Zacks Equity Research

Nektar (NKTR) and Bristol-Myers announce that the bempeg plus Opdivo regimen fails to meet the primary endpoint of progression-free survival and objective response rate in a late-stage melanoma study.

If You Invested $1000 in Eli Lilly 10 Years Ago, This Is How Much You'd Have Now

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Eli Lilly (LLY) closed at $269, marking a +1.01% move from the previous day.

The Zacks Analyst Blog Highlights : Eli Lilly, Nike, Micron Technology, Bayer Aktiengesellschaft, and Valero Energy

by Zacks Equity Research

Eli Lilly, Nike, Micron Technology, Bayer Aktiengesellschaft, and Valero Energy are included in today's analyst blog.